Nearsightedness Clinical Trials

Find Nearsightedness Clinical Trials Near You

Spectacle Lenses Utilising P.A.U.S.E.® Technology for Slowing Down Myopia Progression in Vietnamese Children: A Prospective, Masked, Controlled, Randomised, Clinical Trial

Status: Active_not_recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this clinical trial is to learn if spectacle lenses using Phase Alteration Utilising Sub Elements (P.A.U.S.E.®) technology works to slow down the rate of myopia progression in myopic children. The first stage of the trial compares P.A.U.S.E.® spectacle lenses to single vision spectacle lenses in myopic children and the second stage looks at the rate of myopia progression in children while wearing P.A.U.S.E.® spectacle lenses. The main questions to answer are: Do P.A.U.S.E.® spectacle lenses slow down the rate of axial length growth? Do P.A.U.S.E.® spectacle lenses slow down the rate of increase in myopic refractive error? Researchers will compare P.A.U.S.E.® spectacle lenses to a single vision spectacle lens for 12 months followed by assessing P.A.U.S.E.® spectacle lenses for slowing down myopia progression for another 12 months. Participants will be initially randomly allocated to wear either P.A.U.S.E.® spectacle lenses or single vision spectacle lenses and visit the clinic on five occasions over the first 12 month period. After completing the first 12 months, all participants will wear P.A.U.S.E.® spectacle lenses and visit the clinic on three occasions over the second 12 month period.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 6
Maximum Age: 14
Healthy Volunteers: f
View:

• Be between 6-14 years inclusive at time of enrolment.

• Have:

‣ Read the Informed Assent.

⁃ Been explained the Informed Assent.

⁃ Indicated an understanding of the Informed Assent.

⁃ Signed the Informed Assent.

• Have their parent / legal guardian:

‣ Read the Informed Consent.

⁃ Been explained the Informed Consent.

⁃ Indicated an understanding of the Informed Consent.

⁃ Signed the Informed Consent.

• Along with their parent / legal guardian, be capable of comprehending the nature of the study, and be willing and able to adhere to study requirements.

• Along with their parent / legal guardian, agree to maintain the visit and prescribed wearing schedule.

• Agree to wear allocated spectacles for a minimum of 5 days per week, at least 6 hours per day for the duration of the study and to inform the investigator if their schedule is interrupted.

• Be in good general health, based on the parent's / legal guardian's knowledge.

• Have best-corrected high contrast visual acuity based on manifest refraction of 0.10 logMAR (Snellen: 20/25, 6/7.6; Decimal: 0.8) or better in each eye.

• Meet the following criteria determined by cycloplegic autorefraction at Baseline:

• o-5.00 D ≤ spherical equivalent ≤ -0.75 D and sphere component ≤ -0.50 DS. o-1.50 DC ≤ astigmatic component ≤ 0 DC. o\|Spherical equivalent anisometropia\| ≤ 1.00 D.

Locations
Other Locations
Viet Nam
Hai Yen Eye Care
Ho Chi Minh City
Time Frame
Start Date: 2024-09-14
Completion Date: 2027-10
Participants
Target number of participants: 205
Treatments
Active_comparator: Assigned Intervention 1
Single vision spectacle lens
Experimental: Assigned Intervention 2
P.A.U.S.E. spectacle lens 1
Experimental: Assigned Intervention 3
P.A.U.S.E. spectacle lens 2
Related Therapeutic Areas
Sponsors
Collaborators: Brighten Optix Corporation
Leads: nthalmic Pty Ltd

This content was sourced from clinicaltrials.gov